ClinicalTrials.gg
RecruitingNCT06947213Updated Apr 27, 2025

Orthorexia Nervosa in Postmenopausal Osteoporosis

An observational study in Osteoporosis, sponsored by Beylikduzu State Hospital. Recruiting at 1 site in Turkey. Open to female participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Beylikduzu State Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
128
Ages
55 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Osteoporosis with a site in Turkey — 14 open to participants now, 17 under way, none of them phase 3. Osteoporosis · Turkey.

Planned enrollment
16th of 36
128 · median 107
Started
2025
with 10 others
Observational
36 of 67
10 open now
Primary completion
2025-05
later than 4 of 16 live
Registered
46th of 67
by date
Lead sponsor
4 of 67
Beylikduzu State Hospital

Among the 67 studies in Osteoporosis with a site in Turkey, this one is the 16th largest by planned enrollment of the 36 observational ones that give a count, is one of 11 that started in 2025, is one of 36 observational ones, reaches primary completion later than 4 of the 16 other live ones, and was the 46th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

14 of the 67 studies in Osteoporosis with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 55 Years to 75 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Osteoporosis with a site in Turkey, or all of them as a file.
02

Study summary

A total of 64 female patients diagnosed with osteoporosis based on dual-energy X-ray absorptiometry (DXA) measurements performed within the last six months, and 64 age-matched healthy controls without osteoporosis, will be included in our study. Sociodemographic data such as age, sex, height, weight, and BMI will be recorded. Additionally, information regarding the duration of osteoporosis diagnosis, current treatments, history of fractures, history of falls, comorbidities, and smoking status will be collected. Femoral neck and L1-L4 T-scores and bone mineral density values obtained from existing DXA scans will be documented. Orthorexia nervosa-related symptoms will be assessed using the ORTO-11 scale, mood will be evaluated using the Hospital Anxiety and Depression Scale (HADS), and body image will be assessed using the Body Appreciation Scale-2.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

The study population will consist of postmenopausal women with osteoporosis and age-matched healthy controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women between 55-75 years
  • Women diagnosed with osteoporosis based on DXA measurements performed within the past six months.
  • Women aged similarly to the osteoporosis group without a diagnosis of osteoporosis (healthy controls).
  • Willingness to participate and provision of written .

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study.
  • Diagnosed psychiatric disorders.
  • Cognitive impairment.
  • Presence of .
  • Presence of endocrine disorders (e.g., hyperthyroidism, Cushing's syndrome).
  • Use of .
  • Use of medications affecting mood.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
128 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. ORTO-11 Scale

    The ORTO-11 assesses orthorexic tendencies, which refer to an unhealthy obsession with healthy eating. It consists of 11 items rated on a 4-point Likert scale. Total scores range from 11 to 44, with lower scores indicating a higher risk of orthorexia nervosa.

    Time frame: Baseline

Secondary outcomes

  1. Body Appreciation Scale-2 (BAS-2)

    The BAS-2 assesses positive body image and appreciation of one's body. It consists of 10 items rated on a 5-point Likert scale (1 = Never, 5 = Always). Total scores range from 10 to 50, with higher scores indicating greater body appreciation.

    Time frame: Baseline

Other outcomes

  1. Hospital Anxiety and Depression Scale (HADS)- Anxiety Score

    The HADS-A subscale evaluates symptoms of anxiety. It consists of 7 items, each scored between 0 and 3. The total score ranges from 0 to 21, with higher scores indicating higher levels of anxiety.

    Time frame: Baseline

  2. Hospital Anxiety and Depression Scale (HADS)- Depression Score

    The HADS-D subscale evaluates symptoms of depression. It consists of 7 items, each scored between 0 and 3. The total score ranges from 0 to 21, with higher scores indicating higher levels of depression.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Beylikdüzü State Hospital
    Istanbul, 34147, Turkey
    Recruiting
    • Büşra Şirin Ahısha, MD · Contactbsrn080@gmail.com · (0212) 856 27 40
    • Büşra Şirin Ahısha, MD · Principal investigator
    • Fatma Nur Kesiktaş, Prof · Sub investigator
    • Nurdan Paker, Prof · Sub investigator
    • Nazlı Derya Buğdaycı, Doc · Sub investigator
    • Yiğit Can Ahısha, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for May 2025, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2025
First posted
Apr 27, 2025
StartActual
Apr 20, 2025
Primary completionEst.
May 20, 2025
CompletionEst.
May 20, 2025
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06947213
Lead sponsor
Beylikduzu State Hospital
Responsible party
Busra Sirin (Principle Investigator, Beylikduzu State Hospital) — Principal investigator
First posted
Apr 27, 2025
Start date
Apr 20, 2025
Primary completion
May 20, 2025 (estimated)
Completion
May 20, 2025 (estimated)
Last update
Apr 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion